Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Folfiri.3 followed by gemcitabine in untreated metastatic pancreatic cancer
2006-005703-34Phase 2Active
- Sponsor
- AGEO
- Start
- Mar 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan, gemcitabine, fluorouracil and folinic acid in pancreatic adenocarcinoma (PDAC), sponsored by AGEO. Primary endpoint: Progression-free survival at 6 months. Started Mar 2007; status: active.
02
Drugs
irinotecangemcitabinefluorouracilfolinic acid
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2006-005703-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005703-34.